The N.N. Alexandrov National Centre beings Phase II case-control clinical trial of its immune-oncology agent called Elenagen.
Inoperable late-stage cancer patients with triple-negative breast cancer, ovarian cancer, stomach cancer or prostate cancer will be randomized and then subsequently receive either standard chemotherapy or chemotherapy combined with Elenagen. For each disease, the experimental and control groups will be compared for time to disease progression, overall survival, as well as tumor regression and the dynamics of clinical conditions. One can also expect a reversal of a tumor grade to an operable stage, which would make the tumor surgically removable.
What is Elenagen?
Elenagen was developed by CureLab Oncology, Inc., a Boston-based biotech startup which provided the product to Belarussian college. Aldevron, Inc. (Fargo, ND) was the contract research manufacturer of the product. Dr. Alex Shneider, CEO of CureLab Oncology reported “Although in the coming year we are planning to start Phase II clinical trials of Elenagen in breast cancer and ovarian cancers in the U.S. and multiple other countries, it is very important for us to begin wit...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).